1. Scrip

Pfizer Touts Elrexfio’s Potential For Community Oncology Use In Myeloma

Second Approval Of BCMA-Directed Bispecific Antibody

 
• By Alaric DeArment

The drug maker is pointing to potential biweekly dosing as raising the possibility for the bispecific’s use in community oncology, though an expert had said it could take some time for that to happen.

Pfizer announced the approval of anti-BCMA bispecific antibody Elrexfio for multiple myeloma • Source: Shutterstock

The number of BCMA-directed therapies for treating multiple myeloma grew as the US Food and Drug Administration gave accelerated approval to Elrexfio (elranatamab-bcmm), Pfizer Inc.’s anti-BCMAxCD3 bispecific antibody. Given its flat dosing, dosing schedule and adverse event profile, the company sees the potential for the drug to gain traction in the community oncology setting rather than staying relegated to academic cancer centers, as BCMA-directed therapies have generally been to date.

The FDA gave the green light to Elrexfio on 14 August for patients who have received at least four prior...

More from New Products

More from Scrip

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.